PE20211390A1 - Compuestos antibacterianos - Google Patents

Compuestos antibacterianos

Info

Publication number
PE20211390A1
PE20211390A1 PE2020000454A PE2020000454A PE20211390A1 PE 20211390 A1 PE20211390 A1 PE 20211390A1 PE 2020000454 A PE2020000454 A PE 2020000454A PE 2020000454 A PE2020000454 A PE 2020000454A PE 20211390 A1 PE20211390 A1 PE 20211390A1
Authority
PE
Peru
Prior art keywords
compounds
membered monocyclic
group
heterocyclyl
relates
Prior art date
Application number
PE2020000454A
Other languages
English (en)
Spanish (es)
Inventor
Paul Meo
Mohammed Nawaz Khan
Cedric Charrier
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20211390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of PE20211390A1 publication Critical patent/PE20211390A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Warehouses Or Storage Devices (AREA)
PE2020000454A 2017-11-03 2018-11-02 Compuestos antibacterianos PE20211390A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds
PCT/GB2018/053183 WO2019086890A1 (en) 2017-11-03 2018-11-02 Antibacterial compounds

Publications (1)

Publication Number Publication Date
PE20211390A1 true PE20211390A1 (es) 2021-07-27

Family

ID=60664899

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2020000454A PE20211390A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos
PE2022000118A PE20221006A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2022000118A PE20221006A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"

Country Status (23)

Country Link
US (2) US11345694B2 (enExample)
EP (2) EP3704105B9 (enExample)
JP (2) JP7348897B2 (enExample)
KR (1) KR102470319B1 (enExample)
CN (1) CN111566099B (enExample)
AU (1) AU2018361828B2 (enExample)
BR (1) BR112020008531A2 (enExample)
CA (1) CA3081423A1 (enExample)
CL (2) CL2020001147A1 (enExample)
CO (1) CO2020005420A2 (enExample)
EA (1) EA202091118A1 (enExample)
ES (1) ES3005164T3 (enExample)
GB (1) GB201718285D0 (enExample)
GE (1) GEP20237522B (enExample)
IL (1) IL274229B2 (enExample)
MA (1) MA50504A (enExample)
MX (2) MX2020004562A (enExample)
NZ (1) NZ764310A (enExample)
PE (2) PE20211390A1 (enExample)
SG (1) SG11202003717UA (enExample)
UA (1) UA128475C2 (enExample)
WO (1) WO2019086890A1 (enExample)
ZA (1) ZA202002093B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
HUE066783T2 (hu) 2018-04-18 2024-09-28 Constellation Pharmaceuticals Inc Metil módosító enzimek modulátorai, ezek készítményei és alkalmazásuk
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
EP4333854A1 (en) * 2021-05-03 2024-03-13 Discuva Ltd. Antibacterial compound
EP4484609A1 (en) 2022-02-21 2025-01-01 Mitsui Chemicals, Inc. Metal member, metal-resin composite body, and method for producing metal member
CN120208965B (zh) * 2025-05-28 2025-08-12 四川大学 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
WO2005085241A1 (ja) * 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2513064B1 (en) * 2009-12-17 2018-07-04 Katholieke Universiteit Leuven K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
PL2731949T3 (pl) * 2011-07-13 2018-10-31 Tiumbio Co., Ltd. 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
KR102405136B1 (ko) * 2014-05-16 2022-06-07 아트리바 테라퓨틱스 게엠베하 인플루엔자 바이러스 및 에스. 아우레우스 공감염에 대한 신규한 항-감염 전략
KR20170122799A (ko) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-β 억제제
US20180044316A1 (en) 2015-03-05 2018-02-15 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Also Published As

Publication number Publication date
AU2018361828A1 (en) 2020-05-28
CA3081423A1 (en) 2019-05-09
MA50504A (fr) 2020-09-09
EP3704105A1 (en) 2020-09-09
CO2020005420A2 (es) 2020-07-31
US20220372027A1 (en) 2022-11-24
CL2020001147A1 (es) 2020-08-14
ES3005164T9 (en) 2025-03-24
CL2021002263A1 (es) 2022-04-01
NZ764310A (en) 2023-04-28
PE20221006A1 (es) 2022-06-15
US11345694B2 (en) 2022-05-31
SG11202003717UA (en) 2020-05-28
IL274229B1 (en) 2023-01-01
EP4606375A3 (en) 2025-11-19
GEP20237522B (en) 2023-08-10
CN111566099A (zh) 2020-08-21
MX2021010246A (es) 2021-09-21
AU2018361828B2 (en) 2023-05-18
CN111566099B (zh) 2023-06-02
JP2021501756A (ja) 2021-01-21
IL274229B2 (en) 2023-05-01
MX2020004562A (es) 2020-08-13
EP4606375A2 (en) 2025-08-27
US20210163460A1 (en) 2021-06-03
EP3704105B1 (en) 2024-10-16
UA128475C2 (uk) 2024-07-24
EP3704105B9 (en) 2025-03-05
IL274229A (en) 2020-06-30
KR102470319B1 (ko) 2022-11-25
ES3005164T3 (en) 2025-03-14
EA202091118A1 (ru) 2020-08-06
KR20200084875A (ko) 2020-07-13
GB201718285D0 (en) 2017-12-20
ZA202002093B (en) 2023-11-29
JP7348897B2 (ja) 2023-09-21
BR112020008531A2 (pt) 2020-10-20
JP2022025116A (ja) 2022-02-09
WO2019086890A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
PE20211390A1 (es) Compuestos antibacterianos
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CL2019003049A1 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats.
CO2022008997A2 (es) Compuestos tricíclicos sustituidos
PE20190709A1 (es) Derivado de pirazolopiridinaque tiene el efecto agonista del receptor de glp-1
AR107032A1 (es) Inhibidores bicíclicos de pad4
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
MX385678B (es) Gamma-carbolinas heterocíclicas fusionadas sustituidas, composiciones farmacéuticas y métodos de uso.
CL2018000292A1 (es) Compuestos farmacéuticos
PE20200008A1 (es) Isoquinolinas como inhibidores de hpk1
PE20191260A1 (es) Compuestos inhibidores del vih
PE20240775A1 (es) Compuestos antivirales
AR109349A1 (es) Compuestos y usos
AR104995A1 (es) Fenoxifenilamidinas sustituidas con halógeno y el uso de estas como fungicidas
PE20141358A1 (es) Polimorfos de inhibidores de cinasas
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
CU20170073A7 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
PE20190968A1 (es) Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
AR094550A1 (es) Inhibidores de btk
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina